Single Center, Prospective, Randomized, Controlled, Non-significant Risk

Dry Eye Clinical Trial

Official title:

A Randomized Controlled Trial to Evaluate the Efficiency of Serum Tears Made With Genius PRP for Improving Signs and Symptoms in Dry Eye Disease (DED)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03286166
• Other study ID #: TOYOS-GENIUSPRP-17-01
• Status: Withdrawn
• Start date: December 1, 2021
• Est. completion date: October 31, 2022

Study information

• Verified date: December 2023
• Source: Toyos Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A randomized controlled trial to evaluate the efficiency of serum tears made with Genius PRP for improving signs and symptoms in Dry Eye Disease (DED). Single center, Prospective, Randomized, Controlled, Non-significant risk

Description:

Genius PRP is a class II medical device with an 510(k)FDA clearance for platelet and plasma separation for bone graft handling. Subjects will sign the IC form within one week of being having been provided the form, at which time they will undergo the following assessments: - Routine ophthalmology tests (biomicroscopy, BCVA and IOP) including corneal fluorescein staining and lissamine green conjunctival staining - Measurement of tear break up time (TBUT) in both eyes. These values will be used as baseline. - Self-administration of the Eye Dryness Scale; 0-100 visual analogue scale. This score will be used as baseline. - Self-administration of Visual Analog Pain Scale - Eligible subjects will be randomized with right eye to receive PRP and left eye to receive vehicle eye drops in the same dosage. Outcome measures will be assessed in both eyes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: October 31, 2022
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 85 Years

Eligibility

Inclusion Criteria:

• 1) Able to read, understand and sign an Informed Consent (IC) form 2) 22-85 years of age 3) Able and willing to comply with the treatment/follow-up schedule and requirements 4) Tear break up time of less than 10 seconds in both eyes 5) SPK in the conjunctiva and/or cornea of each eye 6) Eye dryness scale of 40 or greater at baseline for each eye 7) Self- reported ocular pain from dry eye disease Exclusion Criteria: 1) Unwilling to discontinue use of contact lenses for the duration of the study 2) Ocular surgery or eyelid surgery, within 3 months prior to screening 3) Neuro-paralysis in the planned treatment area, within 6 months prior to screening 4) Other uncontrolled eye disorders affecting the ocular surface, for example active allergies 5) Punctal plugs placed within past 90 days 6) Pre-cancerous lesions, skin cancer or pigmented lesions in the planned treatment area 7) Uncontrolled infections or uncontrolled immunosuppressive diseases 8) Subjects with current ocular infections. 9) New prescription eye drops for dry eye or glaucoma or omega 3 supplements prescribed within 90 days prior to screening, excluding artificial tears 10) New topical treatments within the area to be treated, or oral therapies, within 3 months prior to screening- except over-the-counter acetaminophen-based analgesics for pain management 11) Change in dosage of any systemic medication, within 3 months prior to screening 12) Anticipated relocation or extensive travel outside of the local study area preventing compliance with follow-up over the study period 13) Legally blind in one or both eyes 14) First IPL treatment, within 3 months prior to screening 15) Any condition revealed during the eligibility screening process whereby the investigator deems the subject inappropriate for this study -

Related Conditions & MeSH terms

• Dry Eye
• Dry Eye Syndromes
• Keratoconjunctivitis Sicca

Locations

Country	Name	City	State
United States	Toyos Clinic	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Toyos Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The difference in the change of EDS score from baseline and the tear breakup time from baseline to follow-up, between study eyes in the study arm and study eyes in the control arm	Change in EDS questionnaire from baseline; Change in TBUT from baseline.	3 months
Secondary	The improvement of signs and visual analog pain scale in the study group is larger than the improvement of signs in the control group	Change in corneal and/or conjunctival SPK; Visual analog pain scale	3 months